腫瘍コンパニオン診断の世界市場2020-2027:製品/サービス別、技術別(IHC、NGS)、疾患別(乳がん、白血病)、最終用途別、地域別

◆英語タイトル:Oncology Companion Diagnostic Market Size, Share & Trends Analysis Report By Product & Service, By Technology (IHC, NGS), By Disease Type (Breast Cancer, Leukemia), By End-use, By Region, And Segment Forecasts, 2020 - 2027
◆商品コード:GV20NV088
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2020年9月18日
◆ページ数:183
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥654,500見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥764,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥984,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、腫瘍コンパニオン診断の世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場要因・動向・範囲、市場動向、競争分析、製品/サービス別市場規模(器具、消耗品、ソフトウェア)、技術別市場規模(PCR、IHC、NGS、ISH/FISH)、疾患別市場規模(乳がん、非小細胞肺がん、結腸直腸癌、黒色腫、白血病)、最終用途別市場規模(病院、病理学/診断研究所、学術医療センター)、地域別市場規模、競争状況などの項目を掲載しています。
・調査手法・範囲
・エグゼクティブサマリー
・市場要因・動向・範囲
・市場動向
・競争分析
・腫瘍コンパニオン診断の世界市場規模:製品/サービス別(器具、消耗品、ソフトウェア)
・腫瘍コンパニオン診断の世界市場規模:技術別(PCR、IHC、NGS、ISH/FISH)
・腫瘍コンパニオン診断の世界市場規模:疾患別(乳がん、非小細胞肺がん、結腸直腸癌、黒色腫、白血病)
・腫瘍コンパニオン診断の世界市場規模:最終用途別(病院、病理学/診断研究所、学術医療センター)
・腫瘍コンパニオン診断の世界市場規模:地域別
・競争状況
【レポートの概要】

Oncology Companion Diagnostic Market Growth & Trends

The global oncology companion diagnostic market size is expected to reach USD 5.7 billion by 2027, expanding at a CAGR of 12.7%, according to a new report by Grand View Research, Inc. Expanding access to important genomic information with the aid of companion diagnostics enables informed decision making for designing the targeted treatment approaches for their patients, thereby increasing demand for comprehensive genomic testing and oncology companion diagnostics.

The commercial launch of drugs including Gleevec (imatinib) and Herceptin (trastuzumab) that require Companion Diagnostics (CDx) testing before prescription has increased revenue generation in the oncology companion diagnostics field. This growth is expected to continue in the future owing to a substantial number of CDx associated oncology drugs in clinical trials. Apart from functioning as exclusive or inclusive tests for therapies, CDx also plays a crucial role during participant selection in clinical trials. This is because there is an increased potential for a novel drug candidate to show a better response rate if the patient has its biomarker target.

The economic incentives associated with the use of CDx have encouraged drug developers to combine their drugs with diagnostic tests. However, the diagnostic manufacturers face conflicting demands from payers/providers on one hand and drug manufacturers on the other hand. The regulatory bodies also have stringent policies to align the development timelines of diagnostics and drugs. Therefore, the diagnostic companies are expected to broaden their scope of CDx development instead of focusing on the attainment of a match between a single diagnostic with a specific drug.

Oncology Companion Diagnostic Market Report Highlights

• The product segment held the largest market share in 2019 owing to increased adoption and usage rate of CDx tests

• A significant increase in the approval rate of CDx and a rise in investments for co-development of drugs and their CDx is expected to increase the revenue generation in the product segment

• Consumables occupied a major share of the product segment owing to the frequent use and purchase of media, buffers, reagents, and other consumables required for CDx assay

• Immunohistochemistry (IHC) occupied a major portion of the technology segment owing to the benefits offered by IHC technology including cost and time effectiveness, the suitability of the technique for small tumor types, high adoption of IHC for routine oncology CDx, and low technological requirements associated with IHC

• Presence of a substantial number of FDA approved IHC based CDx assays such as EGFR pharmDx Kits, ER/PR pharmDx Kits, HercepTest Kits, PD-L1 IHC 28-8 pharmDx, VENTANA PD-L1 (SP142) Assay, VENTANA ALK (D5F3) CDx Assay, and VENTANA ALK IHC assay is also expected to increase revenue generation within the IHC segment

• The Non-Small Cell Lung Cancer (NSCLC) segment dominated the market in 2019 and is expected to maintain its dominance during the forecast period

• NSCLC is a lung cancer subtype that accounts for approximately 84.0% of all cases of lung cancer. According to data published by the American Cancer Society (ACS), in 2020, around 228,820 new cases of lung cancer are projected to be diagnosed in the U.S.

• The breast cancer and leukemia segments are expected to grow with substantial rates owing to a rise in the number of cancer cases

• The hospital segment held the largest share in the market in 2019 and is expected to exhibit a considerable growth rate, owing to a rise in the number of cancer diagnostic tests in the hospitals

• North America dominated the market in 2019 owing to the presence of a substantial number of players in this region, as well as the presence of a large number of FDA-approved CDx solutions in cancer therapeutics

• Advancements in technologies and improvements in the economic condition are anticipated to drive the market at the fastest growth rate in the Asia Pacific

• The presence of communities in Asian countries that are actively involved in monitoring and discovery of genetic biomarkers is expected to positively influence the market

• The key players in the market are involved in mutually beneficial partnerships with global entities, including sponsors and diagnostic commercialization partners, which enables them to leverage their market potential globally.

【レポートの目次】

Table of Contents

Chapter 1. Methodology and Scope
1.1 Research Assumptions
1.2 Research Methodology
1.3 Information Procurement
1.4 Information or Data Analysis
1.5 Market Formulation & Validation
1.6 Market Scope and Definitions
1.7 Model
1.7.1 Market study, by Cancer Incidence
1.7.2 Market study, by Technology
1.7.3 Market study, by Company Penetration
1.7.4 Regional analysis
1.8 Global Market: CAGR Calculation
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
Chapter 2. Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
2.4 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Trends and Outlook
3.2 Market Segmentation and Scope
3.3 Market Lineage Outlook
3.4 Technology Timeline
3.5 Pricing Analysis
3.6 Companion Diagnostics Regulatory Environment
3.6.1 Companion diagnostics regulatory environment, U.S.
3.6.2 Companion diagnostics regulatory environment, Europe
3.6.3 Companion diagnostics regulatory environment, Asia Pacific
3.7 Companion Diagnostics Reimbursement Environment
3.7.1 Issues in technology assessment and payer decision-making
3.7.2 Potential risks and benefits of pharmacogenomics from the payer perspective
3.8 Reimbursement Environment, by region (North America, Europe, Asia Pacific, Latin America, MEA)
3.8.1 North America
3.8.2 Europe
3.8.3 Asia pacific
3.8.4 Latin America
3.8.5 Middle East & Africa (MEA)
3.9 Business Environment Analysis
3.9.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.9.2 Porter’s Five Forces Analysis
3.10 Penetration and Growth Prospect Mapping for Product, 2019 (USD Million)
Chapter 4 Market Dynamics
4.1 Market driver analysis
4.1.1 Accelerating demand for targeted cancer treatment & tailored drugs
4.1.2 Collaborations between diagnostic and pharma entities
4.1.3 Rise in approval rate for companion diagnostics
4.1.4 Rise in cancer incidence across the globe
4.2 Market Restraint Analysis
4.2.1 Broken clinical diagnostic testing landscape
4.2.2 Constraints associated with the clinical implementation of companion diagnostic tests
4.3 Market Opportunity Analysis
4.3.1 Increase in adoption of companion diagnostics for precision medicine
4.4 Market Challenge Analysis
4.4.1 Reimbursement Challenges associated with companion diagnostic tests
Chapter 5 Competitive Analysis
5.1 Strategy Framework
5.2 Market Participation Categorization
5.3 Company Market Position Analysis, 2019
5.3.1 CDx penetration
5.3.2 Geographical presence
5.3.3 Product portfolio
5.3.4 Strategic Initiatives
5.4 Major Deals & Strategic Alliances Analysis
5.4.1 Acquisition
5.4.2 Collaboration & partnership
5.4.3 Agreement
5.5 Market Entry Strategies
Chapter 6 Product & Service Business Analysis
6.1 Oncology companion diagnostics market: Product & Service Movement Analysis
6.2 Product
6.2.1 Oncology companion diagnostics market for the product, 2016 – 2027 (USD Million)
6.2.2 Instruments
6.2.2.1 Oncology companion diagnostics instruments market, 2016 – 2027 (USD Million)
6.2.3 Consumables
6.2.3.1 Oncology companion diagnostics consumables market, 2016 – 2027 (USD Million)
6.2.4 Software
6.2.4.1 Oncology companion diagnostics Software market, 2016 – 2027 (USD Million)
6.3 Service
6.3.1 Oncology companion diagnostics service market, 2016 – 2027 (USD Million)
Chapter 7 Technology Business Analysis
7.1 Oncology companion diagnostics market: Technology Movement Analysis
7.2 PCR
7.2.1 Oncology companion diagnostics market for PCR, 2016 – 2027 (USD Million)
7.3 NGS
7.3.1 Oncology companion diagnostics market for NGS, 2016 – 2027 (USD Million)
7.4 IHC
7.4.1 Oncology companion diagnostics market for IHC, 2016 – 2027 (USD Million)
7.5 ISH/FISH
7.5.1 Oncology companion diagnostics market for ISH/FISH, 2016 – 2027 (USD Million)
7.6 Other Technologies
7.6.1 Oncology companion diagnostics market for OTHER TECHNOLOGIES, 2016 – 2027 (USD Million)
Chapter 8 Disease Type Business Analysis
8.1 Oncology companion diagnostics market: Disease Type Movement Analysis
8.2 Breast Cancer
8.2.1 Oncology companion diagnostics market for breast cancer, 2016 – 2027 (USD Million)
8.3 Non-Small Cell Lung Cancer
8.3.1 Oncology companion diagnostics market for NSCLC, 2016 – 2027 (USD Million)
8.4 Colorectal Cancer
8.4.1 Oncology companion diagnostics market for colorectal cancer, 2016 – 2027 (USD Million)
8.5 Leukemia
8.5.1 Oncology companion diagnostics market for leukemia, 2016 – 2027 (USD Million)
8.6 Melanoma
8.6.1 Oncology companion diagnostics market for melanoma, 2016 – 2027 (USD Million)
8.7 Prostate Cancer
8.7.1 Oncology companion diagnostics market for prostate cancer, 2016 – 2027 (USD Million)
8.8 Other Cancer Types
8.8.1 Oncology companion diagnostics market for other cancer types, 2016 – 2027 (USD Million)
Chapter 9 End-use Business Analysis
9.1 Oncology companion diagnostics market: End-use Movement Analysis
9.2 Hospital
9.2.1 Global Oncology companion diagnostics market for the hospital, 2016 – 2027 (USD Million)
9.3 Pathology/Diagnostic Laboratory
9.3.1 Global Oncology companion diagnostics market for Pathology/Diagnostic Laboratory, 2016 – 2027 (USD Million)
9.4 Academic Medical Center
9.4.1 Global Oncology companion diagnostics market for Academic Medical Center, 2016 – 2027 (USD Million)
Chapter 10 Regional Business Analysis
10.1 Oncology companion diagnostics market: Regional Movement Analysis, 2019 & 2027
10.2 North America
10.2.1 North America Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.2.2 The U.S.
10.2.2.1 U.S. Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.2.2.2 U.S. Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.2.2.3 U.S. Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.2.2.4 U.S. Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.2.2.5 U.S. Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.2.3 Canada
10.2.3.1 Canada Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.2.3.2 Canada Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.2.3.3 Canada Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.2.3.4 Canada Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.2.3.5 Canada Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.3 Europe
10.3.1 Europe Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.3.2 Germany
10.3.2.1 Germany Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.3.2.2 Germany Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.3.2.3 Germany Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.3.2.4 Germany Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.3.2.5 Germany Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.3.3 The U.K.
10.3.3.1 U.K. Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.3.3.2 U.K. Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.3.3.3 U.K. Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.3.3.4 U.K. Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.3.3.5 U.K. Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.3.4 France
10.3.4.1 France Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.3.4.2 France Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.3.4.3 France Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.3.4.4 France Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.3.4.5 France Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.3.5 Italy
10.3.5.1 Italy Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.3.5.2 Italy Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.3.5.3 Italy Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.3.5.4 Italy Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.3.5.5 Italy Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.3.6 Spain
10.3.6.1 Spain Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.3.6.2 Spain Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.3.6.3 Spain Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.3.6.4 Spain Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.3.6.5 Spain Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.4 Asia Pacific
10.4.1 Asia Pacific Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.4.2 Japan
10.4.2.1 JAPAN Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.4.2.2 Japan Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.4.2.3 Japan Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.4.2.4 Japan Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.4.2.5 Japan Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.4.3 China
10.4.3.1 China Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.4.3.2 China Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.4.3.3 China Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.4.3.4 China Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.4.3.5 China Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.4.4 South Korea
10.4.4.1 South Korea Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.4.4.2 South Korea Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.4.4.3 South Korea Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.4.4.4 South Korea Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.4.4.5 South Korea Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.4.5 Singapore
10.4.5.1 Singapore Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.4.5.2 Singapore Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.4.5.3 Singapore Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.4.5.4 Singapore Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.4.5.5 Singapore Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.4.6 Taiwan
10.4.6.1 Taiwan Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.4.6.2 Taiwan Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.4.6.3 Taiwan Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.4.6.4 Taiwan Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.4.6.5 Taiwan Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.4.7 Hong Kong
10.4.7.1 Hong Kong Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.4.7.2 Hong Kong Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.4.7.3 Hong Kong Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.4.7.4 Hong Kong Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.4.7.5 Hong Kong Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.5 Latin America
10.5.1 Latin America Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.5.2 Brazil
10.5.2.1 Brazil Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.5.2.2 Brazil Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.5.2.3 Brazil Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.5.2.4 Brazil Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.5.2.5 Brazil Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.5.3 Mexico
10.5.3.1 Mexico Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.5.3.2 Mexico Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.5.3.3 Mexico Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.5.3.4 Mexico Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.5.3.5 Mexico Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.6 The Middle East and Africa (MEA)
10.6.1 MEA Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.6.2 South Africa
10.6.2.1 South Africa Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.6.2.2 South Africa Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.6.2.3 South Africa Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.6.2.4 South Africa Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.6.2.5 South Africa Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
10.6.3 Saudi Arabia
10.6.3.1 Saudi Arabia Oncology companion diagnostics market estimates and forecast, 2016 – 2027 (USD Million)
10.6.3.2 Saudi Arabia Oncology companion diagnostics market estimates and forecast, by product & service, 2016 – 2027 (USD Million)
10.6.3.3 Saudi Arabia Oncology companion diagnostics market estimates and forecast, by technology, 2016 – 2027 (USD Million)
10.6.3.4 Saudi Arabia Oncology companion diagnostics market estimates and forecast, by disease type, 2016 – 2027 (USD Million)
10.6.3.5 Saudi Arabia Oncology companion diagnostics market estimates and forecast, by end-use, 2016 – 2027 (USD Million)
Chapter 11 Competitive Landscape
11.1 Company Profiles
11.1.1 QIAGEN
11.1.1.1 Company overview
11.1.1.2 Financial Performance
11.1.1.3 Product benchmarking
11.1.1.4 Strategic initiatives
11.1.2 Illumina, Inc.
11.1.2.1 Company overview
11.1.2.2 Financial Performance
11.1.2.3 Product benchmarking
11.1.2.4 Strategic initiatives
11.1.3 F. Hoffmann-La Roche Ltd.
11.1.3.1 Company overview
11.1.3.1.1Foundation Medicine
11.1.3.2 Financial Performance
11.1.3.3 Product benchmarking
11.1.3.4 Strategic initiatives
11.1.4 Thermo Fisher Scientific, Inc.
11.1.4.1 Company overview
11.1.4.2 Financial Performance
11.1.4.3 Product benchmarking
11.1.4.4 Strategic initiatives
11.1.5 Agilent Technologies, Inc.
11.1.5.1 Company overview
11.1.5.2 Financial performance
11.1.5.3 Product benchmarking
11.1.5.4 Strategic initiatives
11.1.6 ARUP Laboratories
11.1.6.1 Company overview
11.1.6.2 Product benchmarking
11.1.7 Abbott
11.1.7.1 Company overview
11.1.7.2 Alere, Inc.
11.1.7.2.1Company overview
11.1.7.3 Financial Performance
11.1.7.4 Product benchmarking
11.1.7.5 Strategic initiatives
11.1.8 Myriad Genetics, Inc.
11.1.8.1 Financial performance
11.1.8.2 Product benchmarking
11.1.8.3 Strategic initiatives
11.1.9 bioMérieux SA
11.1.9.1 Financial performance
11.1.9.2 Product benchmarking
11.1.10 Invivoscribe, Inc.
11.1.10.1 Product benchmarking
11.1.10.2 Strategic initiatives

List of Tables

Table 1 Commercially approved companion diagnostics
Table 1 Diagnostics development and commercialization costs
Table 2 Exemplar regulatory guidance documents for IVDs by agencies
Table 3 Risk-based classification system for IVDs
Table 4 Alternative approaches for reimbursement of companion diagnostics in Europe
Table 5 Comparison of the CDx partnership and Rx development budgets of pharmaceutical companies
Table 6 Companion diagnostic approvals in 2020
Table 7 List of approved companion diagnostics in breast cancer
Table 8 Available molecular diagnostic platforms for NSCLC in the clinic
Table 9 Molecular test for colorectal cancer
Table 10 Molecular diagnostics tests, gene tested for blood cancers
Table 11 North America oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 12 North America oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 13 North America oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 14 North America oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 15 North America oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 16 U.S. oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 17 U.S. oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 18 U.S. oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 19 U.S. oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 20 U.S. oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 21 Canada oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 22 Canada oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 23 Canada oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 24 Canada oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 25 Canada oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 26 Europe oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 27 Europe oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 28 Europe oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 29 Europe oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 30 Europe oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 31 Germany oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 32 Germany oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 33 Germany oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 34 Germany oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 35 Germany oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 36 U.K. oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 37 U.K. oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 38 U.K. oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 39 U.K. oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 40 U.K. oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 41 France oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 42 France oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 43 France oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 44 France oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 45 France oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 46 Italy oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 47 Italy oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 48 Italy oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 49 Italy oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 50 Italy oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 51 Spain oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 52 Spain oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 53 Spain oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 54 Spain oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 55 Spain oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 56 Asia Pacific oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 57 Asia Pacific oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 58 Asia Pacific oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 59 Asia Pacific oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 60 Asia Pacific oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 61 Japan oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 62 Japan oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 63 Japan oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 64 Japan oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 65 Japan oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 66 China oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 67 China oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 68 China oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 69 China oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 70 China oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 71 South Korea oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 72 South Korea oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 73 South Korea oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 74 South Korea oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 75 South Korea oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 76 Singapore oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 77 Singapore oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 78 Singapore oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 79 Singapore oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 80 Singapore oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 81 Taiwan oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 82 Taiwan oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 83 Taiwan oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 84 Taiwan oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 85 Taiwan oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 86 Hong Kong oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 87 Hong Kong oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 88 Hong Kong oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 89 Hong Kong oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 90 Hong Kong oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 91 Latin America oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 92 Latin America oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 93 Latin America oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 94 Latin America oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 95 Latin America oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 96 Brazil oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 97 Brazil oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 98 Brazil oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 99 Brazil oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 100 Brazil oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 101 Mexico oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 102 Mexico oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 103 Mexico oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 104 Mexico oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 105 Mexico oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 106 MEA oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 107 MEA oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 108 MEA oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 109 MEA oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 110 MEA oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 111 South Africa oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 112 South Africa oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 113 South Africa oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 114 South Africa oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 115 South Africa oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
Table 116 Saudi Arabia oncology companion diagnostics market estimates & forecasts, by product & service, 2016 - 2027 (USD Million)
Table 117 Saudi Arabia oncology companion diagnostics product market estimates and forecasts, by type, 2016 - 2027 (USD Million)
Table 118 Saudi Arabia oncology companion diagnostics market estimates and forecasts, by technology, 2016 - 2027 (USD Million)
Table 119 Saudi Arabia oncology companion diagnostics market estimates & forecasts, by disease type, 2016 - 2027 (USD Million)
Table 120 Saudi Arabia oncology companion diagnostics market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)


List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 New cancer cases, by country, 2019
Fig. 9 QFD modeling workflow for company market share assessment
Fig. 10 Regional market share assessment
Fig. 11 Market summary, 2019 (USD Million)
Fig. 12 Market trends & outlook
Fig. 13 Oncology companion diagnostics market
Fig. 14 Regulatory inter-dependencies of CDx and associated drug
Fig. 15 Potential risks and benefits of pharmacogenomics from the payer perspective
Fig. 16 Attributes tested at the pilot-scale implementation of new payment models, U.S.
Fig. 17 Snapshot of U.S. reimbursement model
Fig. 18 Key objectives and conclusions of the research study, May 2020
Fig. 19 SWOT Analysis, By Factor (Political & legal Economic and technological)
Fig. 20 Porter’s Five Forces Analysis
Fig. 21 Penetration and growth prospect mapping, 2019 (USD Million)
Fig. 22 Oncology companion diagnostics market drivers impact
Fig. 23 Major pharma-diagnostic partnership models
Fig. 24 Necessary alliances for the development of successful CDx
Fig. 25 Partnerships of Myriad Genetics for BRACAnalysis CDx
Fig. 26 Estimated number of new cancer cases globally, 2018-2040
Fig. 27 Oncology companion diagnostics market restraints impact
Fig. 28 Barriers to the clinical implementation of CDx tests
Fig. 29 Steps to resolve challenges associated with the clinical implementation of CDx tests
Fig. 30 Oncology companion diagnostics market opportunity impact
Fig. 31 Oncology companion diagnostics market challenge impact
Fig. 32 Strategy framework
Fig. 33 Market participation categorization
Fig. 34 Oncology companion diagnostics, company heat map analysis, 2019
Fig. 35 Oncology companion diagnostics market: Product & service outlook key takeaways
Fig. 36 Oncology companion diagnostics market: Product & service movement analysis
Fig. 37 Global oncology companion diagnostics market for the product, 2016 - 2027 (USD Million)
Fig. 38 Oncology companion diagnostics instruments market, 2016 - 2027 (USD Million)
Fig. 39 Oncology companion diagnostics consumables market, 2016 - 2027 (USD Million)
Fig. 40 Oncology companion diagnostics software market, 2016 - 2027 (USD Million)
Fig. 41 Global oncology companion diagnostics service market, 2016 - 2027 (USD Million)
Fig. 42 Oncology companion diagnostics market: Technology outlook and key takeaways
Fig. 43 Oncology companion diagnostics market: Technology movement analysis
Fig. 44 Global oncology companion diagnostics market for PCR, 2016 - 2027 (USD Million)
Fig. 45 Global oncology companion diagnostics market for NGS, 2016 - 2027 (USD Million)
Fig. 46 Global oncology companion diagnostics market for IHC, 2016 - 2027 (USD Million)
Fig. 47 Global oncology companion diagnostics market for ISH/FISH, 2016 - 2027 (USD Million)
Fig. 48 Global oncology companion diagnostics market for other technologies, 2016 - 2027 (USD Million)
Fig. 49 Oncology companion diagnostics market: Disease type outlook key takeaways
Fig. 50 Oncology companion diagnostics market: Disease type movement analysis
Fig. 51 Global oncology companion diagnostics market for breast cancer, 2016 - 2027 (USD Million)
Fig. 52 Global oncology companion diagnostics market for NSCLC, 2016 - 2027 (USD Million)
Fig. 53 Global oncology companion diagnostics market for colorectal cancer, 2016 - 2027 (USD Million)
Fig. 54 Global oncology companion diagnostics market for leukemia, 2016 - 2027 (USD Million)
Fig. 55 Global oncology companion diagnostics market for melanoma, 2016 - 2027 (USD Million)
Fig. 56 Global oncology companion diagnostics market for prostate cancer, 2016 - 2027 (USD Million)
Fig. 57 Global oncology companion diagnostics market for other cancer types, 2016 - 2027 (USD Million)
Fig. 58 Oncology companion diagnostics market: End-use outlook and key takeaways
Fig. 59 Oncology companion diagnostics market: End-use movement analysis
Fig. 60 Global Oncology companion diagnostics market for the hospital, 2016 - 2027 (USD Million)
Fig. 61 Global Oncology companion diagnostics market for pathology/diagnostic laboratory, 2016 - 2027 (USD Million)
Fig. 62 Global Oncology companion diagnostics market for Academic Medical Center, 2016 - 2027 (USD Million)
Fig. 63 Regional market place: Key takeaway
Fig. 64 Oncology companion diagnostics market: Region movement analysis
Fig. 65 North America
Fig. 66 North America Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 67 The U.S.
Fig. 68 U.S. Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 69 Canada
Fig. 70 Canada Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 71 Europe
Fig. 72 Europe Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 73 Germany
Fig. 74 Germany Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 75 The U.K.
Fig. 76 U.K. Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 77 France
Fig. 78 France Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 79 Italy
Fig. 80 Italy Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 81 Spain
Fig. 82 Spain Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 83 Asia Pacific
Fig. 84 Asia Pacific Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 85 Japan
Fig. 86 Japan Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 87 China
Fig. 88 China Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 89 South Korea
Fig. 90 South Korea Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 91 Singapore
Fig. 92 Singapore Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 93 Taiwan
Fig. 94 Taiwan Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 95 Hong Kong
Fig. 96 Hong Kong Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 97 Latin America
Fig. 98 Latin America Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 99 Brazil
Fig. 100 Brazil Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 101 Mexico
Fig. 102 Mexico Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 103 Middle East & Africa (MEA)
Fig. 104 MEA Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 105 South Africa
Fig. 106 South Africa Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)
Fig. 107 Saudi Arabia
Fig. 108 Saudi Arabia Oncology companion diagnostics market estimates and forecast, 2016 - 2027 (USD Million)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[腫瘍コンパニオン診断の世界市場2020-2027:製品/サービス別、技術別(IHC、NGS)、疾患別(乳がん、白血病)、最終用途別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆